MTClin: Integrating MammaTyper® to predict neoadjuvant therapy response in HER2+ breast cancer [0.03%]
MTClin：在HER2阳性乳腺癌中使用MammaTyper®预测新辅助治疗反应
Eugenia Belcastro,Stefano Marletta,Irene Tornabene et al.
Eugenia Belcastro et al.
Aim: Neoadjuvant therapy (NAT) is the standard of care for most HER2-positive early breast cancer (BC). However, 25 to 50% of patients fail to achieve a pathological complete response (pCR). This study evaluates the CE/IV...
Induction therapy with BRAF/MEK inhibitors versus upfront ipilimumab/nivolumab in poor prognostic advanced melanoma [0.03%]
关于预后不良的晚期黑色素瘤患者采用BRAF/MEK抑制剂诱导治疗对比伊匹木单抗/纳武利尤单抗的一线治疗：BEYONDM试验中期分析结果
M Bloem,A J M van den Eertwegh,J B A G Haanen et al.
M Bloem et al.
Aim: BRAF/MEK inhibitor induction therapy (BRAF/MEK-i) followed by ipilimumab/nivolumab (IPI/NIVO) did not show benefit over upfront IPI/NIVO in unselected advanced melanoma patients in clinical trial setting. We investig...
Disparities in cancer incidence and stage at diagnosis between male and female patients in the Netherlands [0.03%]
荷兰男性和女性患者癌症发病率和诊断时期的差异
Liza A Hoveling,Anouk Eijkelboom,Melinda Schuurman et al.
Liza A Hoveling et al.
Objective: We investigated how sex differences in incidence of cancer and stage at diagnosis manifest across age groups. Methods: A ret...
Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study [0.03%]
二代测序在60岁或以下胰腺癌患者中的临床意义：全国前瞻性队列研究
Gaby J Strijk,Jelle C van Dongen,Willem de Koning et al.
Gaby J Strijk et al.
Background and aims: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options and frequent resistance to standard treatments. This study evaluates the feasibility and clinical impact of comprehensive tumor ...
Subvisual imaging signals as biomarkers of impending lung metastasis: A multicenter pan-cancer study [0.03%]
亚视觉成像信号作为肺转移生物标志物的多中心泛癌研究
Ranze Zhang,Haojiang Li,Lei Ding et al.
Ranze Zhang et al.
Study aim: Early detection of distant metastases is crucial, but current imaging detects them only when radiographically visible. This study reported subvisual chest CT signals could serve as early biomarkers for impendin...
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab [0.03%]
胆道癌的基因组途径改变及其预后影响：来自接受顺铂、吉西他滨和度伐利尤单抗治疗的多国队列的见解
Chiara Pirrone,Umberto Malapelle,Francesco Pepe et al.
Chiara Pirrone et al.
Background: Biliary tract cancers (BTC) are aggressive malignancies with limited therapeutic options. Recent advances have integrated immunotherapy into the standard of care, yet outcomes remain heterogeneous, emphasizing...
Response to Letter Re: TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinoma [0.03%]
关于TP53共突变增加EGFR变异Ⅰ期肺腺癌复发风险的来信回复
Filippo Tommaso Gallina,Daniele Marinelli,Jonathan Spicer
Filippo Tommaso Gallina
Corrigendum to "Dose optimization in cancer drug development: Review and outcome of a multi-stakeholder workshop"[Eur. J. Cancer 226 (2025), 115593] [0.03%]
关于“癌症药物开发中的剂量优化：综述及多利益相关者研讨会结果”的勘误[Eur. J. Cancer 226 (2025), 115593]
Axel Glasmacher,Elena Garralda,Chad Gwaltney et al.
Axel Glasmacher et al.
Specific targeting of the pseudogene RPSAP52 reduces ovarian tumor growth in patient-derived orthoxenograft models [0.03%]
特异性靶向假基因RPSAP52可减少卵巢肿瘤异种移植模型的肿瘤生长
Deepthi Ramesh-Kumar,Anaís Sánchez-Castillo,Marta Soler et al.
Deepthi Ramesh-Kumar et al.
The RPSAP52 pseudogene is transcribed in the opposite direction to the oncofetal gene HMGA2 and is reexpressed in various human cancers. Here, we investigate the impact of RPSAP52 in ovarian cancer (OC) and explore the potential therapeutic...
Real-world efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient biliary tract cancer: An AGEO study [0.03%]
免疫检查点抑制剂在微卫星不稳定性/错配修复缺陷型胆道癌患者中的现实世界疗效：AGO研究
Shaoxiang Huang,Xueyu Wang,Peili Zhang
Shaoxiang Huang